Latest news with #globalMarket
Yahoo
5 days ago
- Business
- Yahoo
E-Commerce Update - ECommerce Market Growth Driven By Technology And Consumer Trends
The global eCommerce platform market is projected to experience significant growth, increasing from $9.07 billion in 2025 to $16.50 billion by 2030, driven by a 12.7% compound annual growth rate (CAGR). This expansion is attributed to rising internet and smartphone penetration and a growing consumer preference for digital shopping. Technological advancements, including artificial intelligence, cloud computing, and big data, are enhancing platform capabilities. Despite challenges from cybersecurity concerns, the market benefits from increasing omnichannel retailing and cross-border trade. Notable growth is expected in the payments & billing subsegment and the health & wellness industry, with Asia Pacific leading due to its technological adoption and expanding digital infrastructure. In other market news, was a notable mover up 24.8% and ending trading at $91.89. At the same time, trailed, down 11.7% to close at CN¥30.97. Adobe's AI initiatives could potentially double its AI-driven revenue by 2025. Click to explore how Adobe's strategic growth in AI could impact your investment decisions. For an in-depth understanding of E-Commerce's evolving landscape, check our Market Insights article, highlighting agentic AI's transformative impact on retail personalization and supply chains. Read it now to stay ahead! Best E-Commerce Stocks ended the day at $351.07 up 3.7%. settled at $126.86 up 3.6%. This week, Alibaba joined the Video Distribution Patent Pool to enhance video streaming technology and licensing solutions. closed at $224.56 up 1.4%. On Tuesday, Sendbird announced a three-year strategic collaboration with AWS to enhance its AI capabilities and expand market reach. Where To Now? Gain an insight into the universe of 267 E-Commerce Stocks, among which are TotalEnergies Marketing Maroc, Abdullah Al-Othaim Markets and Maplebear, by clicking here. Ready For A Different Approach? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sources: Simply Wall St "Ecommerce Platform Market Analysis and Global Forecast Report 2025-2030 | Omnichannel Retailing to Drive Demand, Internet Penetration and Smartphones Fuel Adoption" from Research and Markets on GlobeNewswire (published 08 August 2025) Companies discussed in this article include NasdaqCM:NEGG NasdaqGS:ADBE NYSE:BABA NasdaqGS:AMZN and SZSE:300399. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-08-2025
- Business
- Yahoo
HistoSonics announces acquisition by investor consortium for $2.25bn
HistoSonics has announced a substantial management-led majority stake acquisition by a consortium of investors, including public and private entities, with a transaction that values the company at around $2.25bn. This strategic move is set to expedite the company's growth and facilitate the expansion of the Edison Histotripsy System into new clinical indications and markets, according to a company release. The company will continue under the leadership of CEO and president Mike Blue, alongside his executive team. Blue will also become the chairman of the board on the closing of the transaction. Blue said: 'This new group of partners backs category-defining companies that transform entire industries. 'Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.' The deal enables HistoSonics to broaden its therapeutic reach, targeting not only liver tumours but also pancreas, prostate, and kidney conditions. Established in 2009, the company envisions a future where histotripsy can be applied to a wide array of clinical applications, treating both benign and malignant conditions. The Edison system has reportedly been used to treat over 2,000 individuals at more than 50 US medical centres so far, with plans to install another 50 systems by the year's end. The system is intended for the non-invasive destruction of liver tumours, including unresectable liver tumours, leveraging a non-thermal, mechanical process of focused ultrasound. In October 2023, the company secured marketing authorisation from the US Food and Drug Administration (FDA) for its Edison histotripsy platform. The company is backed by preclinical and clinical research across several organ systems. HistoSonics is actively enrolling subjects in clinical trials for kidney, liver, and pancreas tumours, with further trials slated to begin shortly. The investment syndicate features Bezos Expeditions, K5 Global, and Wellington Management, along with Alpha JWC Ventures and other existing investors such as Venture Investors Health Fund and Alpha Wave Ventures. Lumira Ventures and Early Stage Partners are also part of the investor group. Financial advisory services for HistoSonics were provided by Citi, with Fox Rothschild acting as legal advisers. The investment syndicate was advised by Morgan Stanley & Co and Cooley, with assistance from Orrick while Wilson Sonsini Goodrich & Rosati advised HistoSonics' major existing shareholders. "HistoSonics announces acquisition by investor consortium for $2.25bn" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-08-2025
- Health
- Yahoo
Dystrophic Epidermolysis Bullosa Market Analysis and Forecast, 2025-2035: Topical Therapies Dominate DEB Market as Vyjuvek Secures Leading Position
The global dystrophic epidermolysis bullosa (DEB) market is expanding due to increased awareness, advanced diagnostics, and innovative treatments like Vyjuvek, a topical gene therapy by Krystal Biotech. DEB, a rare genetic condition causing fragile skin, is being diagnosed earlier thanks to improved genetic screening and non-invasive imaging. However, the high costs and limited options for advanced disease stages remain challenges. North America leads the market with superior healthcare infrastructure and ongoing clinical research. The demand for DEB treatments is rising, driven by gene and cell-based solutions. Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Dystrophic Epidermolysis Bullosa Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035" report has been added to global dystrophic epidermolysis bullosa market is driven by rising awareness, advances in early diagnosis, and improved treatment options. DEB, a rare genetic disorder characterized by fragile skin that blisters easily, significantly impairs quality of life and can lead to severe complications such as chronic wounds, scarring, and increased risk of infections. Advances in genetic screening, biomarkers, and non-invasive imaging techniques are enabling earlier and more accurate diagnoses, which is driving the demand for more targeted therapeutic interventions. Additionally, innovations in gene therapy, such as Vyjuvek, and cell-based treatments are offering new hope for patients, improving skin healing and reducing the burden of the challenges including the high costs of novel therapies, limited treatment options for advanced stages of the disease, and variability in patient responses complicate treatment regimens for dystrophic epidermolysis bullosa. Additionally, the rarity of the condition and disparities in healthcare infrastructure limit access to timely and standardized care, especially in low- and middle-income countries. Despite these obstacles, increasing government and private sector investments in rare disease research, along with rising awareness campaigns, are driving market growth by improving early diagnosis, enhancing patient access to treatments for Dystrophic Epidermolysis Bullosa (DEB), such as gene therapies such as Vyjuvek, significantly improve skin healing and reduce blistering, enhancing patients' quality of life. Early diagnosis through advanced genetic screening and non-invasive imaging enables personalized care, while digital health tools and telemedicine improve monitoring and treatment adherence. These advancements are transforming DEB into a more manageable condition, improving patient outcomes and reducing healthcare topical therapies hold the highest market share. This can be attributed to the approval and adoption of Vyjuvek (eremagene geperpavec), a topical gene therapy developed by Krystal Biotech. This approval has positioned Vyjuvek as a leading treatment option, contributing to the dominance of topical therapies in the DEB America holds the highest market share in the dystrophic epidermolysis bullosa market, driven by the region's advanced healthcare infrastructure, robust reimbursement policies, and the presence of leading pharmaceutical companies actively developing and commercializing DEB therapies. Additionally, North America benefits from a high prevalence of DEB, extensive clinical research activities, and a well-established patient support network, all contributing to its leading position in the Drivers for the Global Dystrophic Epidermolysis Bullosa Market: Growing awareness is leading to earlier diagnosis and more identified cases of DEB. Gene therapies and cell-based treatments such as Vyjuvek are addressing DEB's genetic roots, creating demand for innovative solutions. Enhanced diagnostic tools enable quicker and more accurate identification of DEB. Early detection facilitates timely intervention, driving treatment demand. Global initiatives supporting rare diseases, including DEB, are increasing treatment access. Limitations for the Global Dystrophic Epidermolysis Bullosa Market: Advanced therapies, such as gene and cell-based treatments, come with high price tags, limiting their accessibility. Despite progress, gene and cell-based therapies for DEB are still in the early stages of development and are not widely available. The approval process for novel therapies in DEB can be slow and complex, hindering the timely availability of new treatments. Key Market Players and Competition SynopsisA detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global dystrophic epidermolysis bullosa market. Leading players in the global dystrophic epidermolysis bullosa market include: Krystal Biotech Castle Creek Biosciences Abeona Therapeutics Amryt Pharma Phoenix Tissue Repair InMed Pharmaceuticals Eloxx Pharmaceuticals RegeneRx Biopharmaceuticals Phoenicis Therapeutics BPGbio Key Topics Covered:1. Global Dystrophic Epidermolysis Bullosa Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.4 Regulatory Landscape1.5 Pipeline Analysis1.6 Market Dynamics2. Global Dystrophic Epidermolysis Bullosa Market (by Therapy Type), Value ($million), 2023-20352.1 Gene Therapy2.2 Cell-Based Therapy2.3 Topical Therapies2.4 Small Molecule Therapy2.5 Others3. Global Dystrophic Epidermolysis Bullosa Market (by Region), Value ($Million), 2023-20353.1 North America3.2 Europe3.3 Asia-Pacific3.4 Rest-of-the-World4. Competitive Landscape and Company Profiles4.1 Competitive Landscape4.1.1 Mergers and Acquisitions4.1.2 Partnership, Alliances and Business Expansion4.1.3 New Offerings4.1.4 Regulatory Activities4.1.5 Funding Activities4.2 Company Profiles Krystal Biotech Castle Creek Biosciences Abeona Therapeutics Amryt Pharma Phoenix Tissue Repair InMed Pharmaceuticals Eloxx Pharmaceuticals RegeneRx Biopharmaceuticals Phoenicis Therapeutics BPGbio For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
25-07-2025
- Automotive
- Yahoo
3D Weaving Market worth $59.7 million by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., July 25, 2025 /PRNewswire/ -- The global 3D weaving market is expected to grow from USD 32.8 million in 2025 to USD 59.7 million by 2030, growing at a CAGR of 12.7% according to a new report by MarketsandMarkets™. The growth of renewable energy and infrastructure projects is a major driver for the 3D weaving machinery market, as it boosts the demand for lightweight, durable, and corrosion-resistant composite parts. Uses such as wind turbine blades and structural reinforcements in construction benefit from the superior strength and durability of 3D woven fabrics. 3D weaving machines allow for efficient, near-net-shape production of these complex parts, making them perfect for sustainable and high-performance applications. As global investments in clean energy and infrastructure increase, the demand for advanced 3D weaving technology is expected to rise accordingly. Download PDF Brochure: Browse in-depth TOC on "3D Weaving Market" 141 – Tables43 – Figures146 – Pages 3D Weaving Market Report Scope: Report Coverage Details Market Revenue in 2025 $ 32.8 million Estimated Value by 2030 $ 59.7 million Growth Rate Poised to grow at a CAGR of 12.7% Market Size Available for 2021–2030 Forecast Period 2025–2030 Forecast Units Value (USD Million/Billion) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered By product type, end-use industry, application, and region Geographies Covered North America, Europe, Asia Pacific, and Rest of World Key Market Challenge Extended product development and qualification cycles Key Market Opportunities Rising demand for customized military and tactical gear Key Market Drivers Customization and complex geometry capabilities The automotive end-use industry is expected to grow at the second highest CAGR in the 3D weaving market during the forecast period. The automotive end-use industry is projected to grow at the second-highest CAGR in the 3D weaving market during the forecast period, driven by the increasing demand for lightweight and high-performance materials that improve fuel efficiency and vehicle safety. Because of their superior strength-to-weight ratio and design flexibility, 3D woven composites are increasingly used in structural components, crash protection parts, and interior panels. Additionally, the shift toward electric vehicles and stricter emission standards is speeding up the adoption of advanced composite technologies in automotive manufacturing. The composite textile weaving machines segment is expected to register the highest CAGR in the market, by product type. The composite textile weaving machines segment is expected to register the highest CAGR during the forecast period, mainly because of their ability to adapt to changing material innovations and custom engineering requirements. Unlike traditional weaving systems, these machines provide flexibility to work with various technical fibers and can be customized to produce high-value, application-specific woven structures. This flexibility is attracting increasing interest from industries developing next-generation components, such as crash-resistant automotive frames, thermally stable aerospace panels, and complex biomedical implants. The capacity to support prototyping and full-scale production makes composite textile weaving machines a strategic investment for companies focused on performance differentiation and innovation-driven growth. Inquiry Before Buying: North America is projected to witness the second-highest CAGR in the 3D weaving market during the forecast period. North America is expected to have the second-fastest growth rate in the 3D weaving industry from 2025 to 2030. This growth is driven by strong demand from the aerospace, defense, and advanced automotive industries, along with a focus on innovation and developing composite materials. The region hosts many top aerospace and defense OEMs, including Boeing, Lockheed Martin, and Raytheon, which are investing in new lightweight, high-strength materials to improve fuel efficiency, structural performance, and combat capability. These strategic goals have sped up the adoption of 3D woven composites in key parts such as aircraft fuselage sections, turbine components, and military armor systems. Additionally, North America benefits from a well-established ecosystem of R&D institutions, university research centers, and private sector initiatives dedicated to advancing textile engineering and composite technologies. The growing trend toward electrification and lightweighting in the automotive industry, along with increasing interest in smart textiles and medical composites, is also broadening application areas. With its advanced manufacturing infrastructure and innovation-driven market dynamics, North America is well-positioned to maintain strong growth in the 3D weaving market through 2030. Major companies in the 3D weaving companies include Lindauer DORNIER GmbH (Germany), Stäubli International AG (Switzerland), Unspun (US), Hefei Fanyuan Instrument Co., Ltd (China), and VÚTS a.s. (Czech Republic). Get 10% Free Customization on this Report: Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting See More Latest Semiconductor Reports: Control Valve Market by Material (Stainless Steel, Cast Iron, Cryogenic, Alloy Based), Actuators (Pneumatic, Electrical, Hydraulic), Size, Rotary Valves (Ball, Butterfly, Plug), Linear Valves (Globe, Diaphragm), Industry - Global Forecast to 2030 UV LED Market by UV-A, UV-B, UV-C, UV Curing (Printing, Adhesives), Disinfection, Medical & Scientific (Equipment Sterilization, Tanning, Teeth Brightening), Security, Lithography, Power Output (Less than 1w, 1W-5W, Above 5W) Global - Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Web Site: Insight: Source: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
15-07-2025
- Business
- Bloomberg
David Sacks on Nvidia Chips to China, US Tech Stack
White House AI and Crypto Czar David Sacks discusses the easing of curbs on the sale of Nvidia and Advanced Micro Devices chips to China, boosting US tech exports in the global market, addressing security concerns around chip technology, and energy investment to support AI. (Source: Bloomberg)
